Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Michael Friis

Head of Equities

Michael Friis portrait

Coverage

HydractAudientesRealfictionShape RoboticsScape TechnologiesGreenMobilityCurasightOrderYOYOPenneoPhotocatOdicoAgillicBawat Water TechnologiesImperoMapsPeopleNNITNordic SolarScandinavian Medical SolutionsWindowMaster InternationalGomSpace GroupCABA CapitalAscelia PharmaEmbla MedicalBioPortoGubraExpreS2ion Biotech Holding

Latest content

ShowingAll content types

Rovsing (One-pager): Near-term headwinds, growing tender activity, and a new ESA cycle ahead

Research 19.02.2026 klo 16.45 by Michael Friis, Victor Skriver
Rovsing

GomSpace: Presentation of 2025 Full-Year results (Recording)

Analyst Comment 19.02.2026 klo 14.55 by Michael Friis
GomSpace Group

ExpreS2ion: Presentation of Q4 2025 report (Recording)

Analyst Comment 19.02.2026 klo 14.42 by Michael Friis
ExpreS2ion Biotech Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Ascelia Pharma: Video presentation of the 2025 results

Analyst Comment 06.02.2026 klo 17.14 by Michael Friis
Ascelia Pharma

BioPorto: Strong end to 2025, guidance points to continued momentum in 2026

Analyst Comment 06.02.2026 klo 08.00 by Michael Friis
BioPorto

Aselia pharma: Partnering discussions for Orviglance continues to advance

Analyst Comment 05.02.2026 klo 13.42 by Michael Friis
Ascelia Pharma

Embla Medical: Recording of FY 2025 results presentation

Analyst Comment 03.02.2026 klo 15.59 by Michael Friis
Embla Medical

ExpreS2ion: Incremental Phase I data strengthen early biological validation of ES2B-C001

Analyst Comment 03.02.2026 klo 13.00 by Michael Friis
ExpreS2ion Biotech Holding

GreenMobility: Recording of preliminary 2025 results and 2026 guidance presentation

Analyst Comment 30.01.2026 klo 09.08 by Michael Friis
GreenMobility

Columbus: Growth challenged, but sequential margin improvement

Analyst Comment 27.01.2026 klo 15.18 by Michael Friis
Columbus
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.